Clinical trials: sponsored by Addpharma Inc.
Hypertension
Evaluate the Pharmacokinetic Interaction and the Safety of AD-2321 and AD-2322
To evaluate the pharmacokinetic interactions of AD-2321, AD-2322 in healthy adult volunteers.
- Trial name
- NCT07312799
- Testing
- Treatment A(AD-2321), Treatment B(AD-2322), Treatment C(AD-2321+AD-2322)
- Where
- South Korea
- Volunteers
- 41 people, healthy volunteers welcome
- Sponsor
- Addpharma Inc.
Mixed Dyslipidemia
A Study to Compare to PK Characteristics and Safety Profiles Between AD-117 and AD-117A
Primary endpoint of this study is to evaluate the pharmacokinetic characteristics of AD-117 in healthy subjects.
- Trial name
- NCT07152873
- Testing
- AD-117, AD-117A
- Where
- South Korea
- Volunteers
- 60 people, healthy volunteers welcome
- Sponsor
- Addpharma Inc.
Primary Hypertension
A Study to Compare to PK Characteristics and Safety Profiles Between AD-227 and Co-administration of AD-227A and AD-227B
Primary endpoint of this study is to evaluate the pharmacokinetic characteristics of AD-227 in healthy subjects.
- Trial name
- NCT06884085
- Testing
- Co-administration of AD-227A and AD-227B, Administration of AD-227
- Where
- South Korea
- Volunteers
- 70 people, healthy volunteers welcome
- Sponsor
- Addpharma Inc.
Gastric Ulcer
The Study Compare and Evaluate the Safety and PK Data of a Single Dose Administration of 'AD-115A' or 'AD-1151'
The study compare and evaluate the safety and pharmacokinetic characteristics of a single dose administration of 'AD-115A' or 'AD-1151' in healthy adults.
- Trial name
- NCT06902818
- Testing
- AD-115A, AD-1151
- Where
- South Korea
- Volunteers
- 46 people
- Sponsor
- Addpharma Inc.
Primary Hypercholesterolaemia
A Study to Evaluate the Safety and Pharmacokinetics of AD-228A Compared to Coadministration of AD-2281 and AD-2282
Primary endpoint of this study is to evaluate the pharmacokinetic characteristics of AD-228A in healthy subjects.
- Trial name
- NCT06858865
- Testing
- AD-228A, AD-2281 and AD-2282
- Where
- South Korea
- Volunteers
- 60 people, healthy volunteers welcome
- Sponsor
- Addpharma Inc.
Mixed Dyslipidemia
The Food Effect on PK Characteristics and Safety Profiles of PA-111
Primary endpoint of this study is to evaluate the pharmacokinetic characteristics of PA-111 in healthy subjects.
- Trial name
- NCT06976489
- Testing
- PA-111
- Where
- South Korea
- Volunteers
- 40 people, healthy volunteers welcome
- Sponsor
- Addpharma Inc.
Mixed Dyslipidemia
A Study to Compare to PK Characteristics and Safety Profiles Between PA-111 and PA-111A
Primary endpoint of this study is to evaluate the pharmacokinetic characteristics of PA-111 in healthy subjects.
- Trial name
- NCT06932705
- Testing
- PA-111, PA-111A
- Where
- South Korea
- Volunteers
- 48 people, healthy volunteers welcome
- Sponsor
- Addpharma Inc.
Gastroesophageal Reflux Disease (GERD)
A Study to Compare PK/PD Characteristics and Safety Profiles Between AD-120 and AD-120A
Primary endpoint of this study is to evaluate the pharmacokinetic and pharmacodynamic characteristics of AD-120 in healthy subjects.
- Trial name
- NCT06916130
- Testing
- AD-120A, AD-120
- Where
- South Korea
- Volunteers
- 48 people, healthy volunteers welcome
- Sponsor
- Addpharma Inc.
Hypertension,Essential
A Study to Evaluate the Efficacy and Safety of AD-223
The purpose of this study is to evaluate the efficacy and safety of AD-223
- Trial name
- NCT06052748
- Testing
- AD-223A, AD-223B, AD-223C
- Where
- South Korea
- Volunteers
- 502 people
- Sponsor
- Addpharma Inc.
Primary Hypercholesterolaemia
A Study to Compare PK Characteristics and Safety Profiles Between AD-228B and AD-2284
Primary endpoint of this study is to evaluate the pharmacokinetic characteristics of AD-228B in healthy subjects.
- Trial name
- NCT06884098
- Testing
- AD-228B, AD-2284
- Where
- South Korea
- Volunteers
- 60 people, healthy volunteers welcome
- Sponsor
- Addpharma Inc.
Mixed Dyslipidemia
A Study to Evaluate the Efficacy and Safety of AD-218
The purpose of this study is to evaluate the efficacy and safety of AD-218
- Trial name
- NCT05400317
- Testing
- AD-218, AD-218A
- Where
- South Korea
- Volunteers
- 520 people
- Sponsor
- Addpharma Inc.
Essential Hypertension
A Study to Evaluate the Efficacy and Safety of Co-administration of AD-227A and AD-227B
The purpose of this study is to evaluate the efficacy and safety of co-administration of AD-227A and AD-227B in patients with essential hypertension
- Trial name
- NCT06441630
- Testing
- AD-227A, AD-227B, AD-227C
- Where
- South Korea
- Volunteers
- 251 people
- Sponsor
- Addpharma Inc.
Hyperlipidemias
A Study to Assess the Safety and Pharmacokinetics of AD-104-A
Primary endpoint of this study is to evaluate the pharmacokinetic characteristics of AD-104-A
- Trial name
- NCT05703282
- Testing
- AD-104-A
- Where
- South Korea
- Volunteers
- 32 people, healthy volunteers welcome
- Sponsor
- Addpharma Inc.
Gastro Esophageal Reflux
A Study to Compare PK/PD Characteristics and Safety Profiles Between AD-212-A and AD-2121
Primary endpoint of this study is to evaluate the pharmacokinetic and pharmacodynamic characteristics of AD-212-A in healthy subjects.
- Trial name
- NCT06025773
- Testing
- Lansoprazole 15 mg, Lansoprazole 15mg/Calcium carbonate 600mg
- Where
- South Korea
- Volunteers
- 24 people, healthy volunteers welcome
- Sponsor
- Addpharma Inc.
Hypertension, Essential, Primary Hypercholesterolemia
Phase 3 Study to Evaluate the Efficacy and Safety of Co-administrated AD-2021 and AD-2022
The purpose of this study is to Evaluate the Efficacy and Safety of Co-administrated AD-2021 and AD-2022
- Trial name
- NCT06448962
- Testing
- AD-2021, AD-2022
- Where
- South Korea
- Volunteers
- 109 people
- Sponsor
- Addpharma Inc.
Hypertension,Essential
Phase III Study to Evaluate the Efficacy and Safety of AD-209
The purpose of this study is to evaluate the efficacy and safety of AD-209
- Trial name
- NCT06348576
- Testing
- AD-209, AD-2091
- Where
- South Korea
- Volunteers
- 280 people
- Sponsor
- Addpharma Inc.
Hypertension, Essential
A Study to Evaluate the Efficacy and Safety of AD-209
The purpose of this study is to evaluate the efficacy and safety of AD-209
- Trial name
- NCT05631990
- Testing
- AD-209, AD-209-1A, AD-209-1B
- Where
- South Korea
- Volunteers
- 221 people
- Sponsor
- Addpharma Inc.
Androgenetic Alopecia
A Study to Evaluate the Efficacy and Safety of AD-208
The purpose of this study is to evaluate the efficacy and safety of AD-208.
- Trial name
- NCT04825561
- Testing
- AD-208, AD-2081
- Where
- South Korea
- Volunteers
- 139 people
- Sponsor
- Addpharma Inc.
Gastroesophageal Reflux Disease
A Study to Compare PK, PD and Safety of the AD-214 and AD-2141
A study to compare safety, pharmacokinetics and pharmacodynamics of AD-214 to AD-2141 in healthy volunteers.
- Trial name
- NCT05062876
- Testing
- AD-214, AD-2141
- Where
- South Korea
- Volunteers
- 41 people, healthy volunteers welcome
- Sponsor
- Addpharma Inc.
Primary Hypercholesterolemia
A Study to Evaluate the Efficacy and Safety of AD-221 and AD-221A
The purpose of this study is to evaluate the efficacy and safety of AD-221 and AD-221A
- Trial name
- NCT05131997
- Testing
- AD-221, AD-221A, AD-221B
- Where
- South Korea
- Volunteers
- 290 people
- Sponsor
- Addpharma Inc.